The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA TransferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, J. N. Mark Glover et al.|Diabetes|2022Cited by 14
Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesitySeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Kunyan Yang et al.|iScience|2025Cited by 2
The antipsychotic dopamine 2 receptor antagonist diphenylbutylpiperidines improve glycemia in experimental obesity by inhibiting succinyl-CoA:3-ketoacid CoA transferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Amanda A. Greenwell et al.|Unknown|2022Cited by 1
118-LB: The Antipsychotic D2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA—3-Ketoacid CoA transferaseSEYED AMIRHOSSEIN TABATABAEI DAKHILI, John R. Ussher, Rabih Abou Farraj et al.|Diabetes|2022Cited by 0
The antipsychotic dopamine 2 receptor antagonist diphenylbutylpiperidines improve glycemia in experimental obesity by inhibiting succinyl-CoA:3-ketoacid CoA transferaseSeyed Amirhossein Tabatabaei Dakhili, John R. Ussher, Amanda A. Greenwell et al.|Unknown|2022Cited by 0